Temporal muscle thickness is not associated with hematotoxicity risk after alkylating chemotherapy in newly diagnosed glioblastoma

Clicks: 9
ID: 333659
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #62 of 65 articles by views in Neuro-Oncology Practice

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Lay Summary Treatment for glioblastoma usually includes chemotherapy, which can cause serious side effects affecting blood cell counts (hematotoxicity). Identifying patients at increased risk for these complications could help guide treatment decisions. We investigated whether temporal muscle thickness, a simple MRI-based marker often used to estimate muscle mass and frailty, could predict hematotoxicity in patients with newly diagnosed glioblastoma. In 222 patients, temporal muscle thickness was not associated with severe hematotoxicity or survival. Instead, female sex and intensified treatment with lomustine plus temozolomide were associated with an increased risk of hematotoxicity.
Reference Key
openalex_W7223297401 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal Neuro-Oncology Practice
Year 2026
DOI
10.1093/nop/npag106
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.